X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Guest post: Continued research and development is critical for ALS patients and families

By Guest Contributor  |    October 25, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years

By Juliet Johnson  |    November 21, 2019
A new analysis from economic consulting firm Vital Transformation shows that Speaker Nancy Pelosi’s drug pricing plan, H.R.3, could result in at least 56 fewer innovative medicines for patients over...   Read More

Pelosi’s radical plan would leave ALS patients behind

By Tom Wilbur  |    October 15, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and leave...   Read More

ICYMI: Fighting for a cure to ALS

By Anne McDonald Pritchett, PhD  |    September 25, 2019
Yesterday at The Atlantic Festival, I had the chance to speak with Amy, a biopharmaceutical researcher focused on amyotrophic lateral sclerosis (ALS). As a young girl, Amy’s father inspired her to...   Read More

New report shows over 500 medicines in development for neurological disorders

By Andrew Powaleny  |    April 18, 2018
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.S. population....   Read More

New PhRMA Report: Medicines in development for patients with rare diseases demonstrate the promise of innovation

By Ieva M. Augstums  |    May 9, 2016
Today, there are 7,000 known rare diseases, or diseases that affect fewer than 200,000 people in the United States. But those suffering from the impact of these diseases have more hope today because...   Read More

Because One Day Isn't Enough

By PhRMA Staff  |    February 28, 2011
Today is Rare Disease Day, a day meant to raise awareness of the 25 million Americans living with diseases that are often little-known and often, unfortunately, undertreated. In conjunction with Rare...   Read More

Searching for Success in ALS

By PhRMA Staff  |    February 10, 2011
Yesterday, our friends at ALS Advocacy Tweeted about the Chart Pack: "Need some #ALS success charts in the next edition!" They can rest assured that America's biopharmaceutical research companies are...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."